Multidisciplinary Intensive Care Research Organization (MICRO), Wellcome Trust-HRB Clinical Research, Department of Clinical Medicine, Trinity Centre for Health Sciences, St James's University Hospital, Dublin, Ireland.
CIBERes, Madrid, Spain.
Intensive Care Med. 2017 Jan;43(1):48-58. doi: 10.1007/s00134-016-4578-y. Epub 2016 Oct 5.
Co-infection is frequently seen in critically ill patients with influenza, although the exact rate is unknown. We determined the rate of co-infection, the risk factors and the outcomes associated with co-infection in critically ill patients with influenza over a 7-year period in 148 Spanish intensive care units (ICUs).
This was a prospective, observational, multicentre study. Influenza was diagnosed using the polymerase chain reaction. Co-infection had to be confirmed using standard bacteriological tests. The primary endpoint of this analysis was the presence of community-acquired co-infection, with secondary endpoints including ICU, 28-day and hospital mortality.
Of 2901 ICU patients diagnosed with influenza, 482 (16.6 %) had a co-infection. The proportion of cases of co-infection increased from 11.4 % (110/968) in 2009 to 23.4 % (80/342) in 2015 (P < 0.001). Compared with patients without co-infection, patients with co-infection were older [adjusted odds ratio (aOR) 1.1, 95 % confidence interval 1.1-1.2; P < 0.001] and were more frequently immunosuppressed due to existing HIV infection (aOR 2.6 [1.5-4.5]; P < 0.001) or preceding medication (aOR 1.4 [1.1-1.9]; P = 0.03). Co-infection was an independent risk factor for ICU mortality (aOR 1.4 [1.1-1.8]; P < 0.02), 28-day mortality (aOR 1.3 [1.1-1.7]; P = 0.04) and hospital mortality (aOR 1.9 [1.5-2.5]; P < 0.001).
Co-infection in critically ill patients with influenza has increased in recent years. In this Spanish cohort, age and immunosuppression were risk factors for co-infection, and co-infection was an independent risk factor for ICU, 28-day and hospital mortality.
在患有流感的危重症患者中经常会发生合并感染,尽管确切的合并感染率尚不清楚。我们在西班牙的 148 家重症监护病房(ICU)中,对 7 年内患有流感的危重症患者的合并感染率、相关危险因素和结局进行了研究。
这是一项前瞻性、观察性、多中心研究。使用聚合酶链反应诊断流感。合并感染必须通过标准的细菌学检测来确认。本分析的主要终点是社区获得性合并感染,次要终点包括 ICU、28 天和住院死亡率。
在 2901 例 ICU 确诊流感的患者中,482 例(16.6%)存在合并感染。合并感染的比例从 2009 年的 11.4%(110/968)增加到 2015 年的 23.4%(80/342)(P<0.001)。与无合并感染的患者相比,合并感染的患者年龄更大[校正优势比(aOR)1.1,95%置信区间 1.1-1.2;P<0.001],并且由于现有的 HIV 感染(aOR 2.6 [1.5-4.5];P<0.001)或先前的药物治疗(aOR 1.4 [1.1-1.9];P=0.03)而更频繁地出现免疫抑制。合并感染是 ICU 死亡率(aOR 1.4 [1.1-1.8];P<0.02)、28 天死亡率(aOR 1.3 [1.1-1.7];P=0.04)和住院死亡率(aOR 1.9 [1.5-2.5];P<0.001)的独立危险因素。
近年来,患有流感的危重症患者的合并感染有所增加。在西班牙这个队列中,年龄和免疫抑制是合并感染的危险因素,合并感染是 ICU、28 天和住院死亡率的独立危险因素。